Skip to main content

Advertisement

Table 2 Association of OPN mRNA expression with selected patient and tumor characteristics

From: Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group

  Low (N = 407) High (N = 407) p value
N (%) N (%)
Age (in years)
 <50 187 (45.9) 159 (39.1) 0.047
 ≥50 220 (54.1) 248 (60.9)  
NPI score
 Median (range) 5.6 (3.0–7.8) 5.5 (3.2–9.0) 0.64
Treatment group
 E-CMF 69 (17.0) 53 (13.0) 0.18
 E-T-CMF 196 (48.1) 192 (47.2)  
 ET-CMF 142 (34.9) 162 (39.8)  
Menopausal status
 Premenopausal 201 (49.4) 172 (42.3) 0.041
 Postmenopausal 206 (50.6) 235 (57.7)  
Type of operation
 Modified radical mastectomy 285 (70.0) 290 (71.3) 0.70
 Breast conserving surgery 122 (30.0) 117 (28.7)  
ER/PgR status
 Negative 65 (17.2) 98 (25.7) 0.004
 Positive 312 (82.8) 283 (74.3)  
Histological grade
 I–II 211 (51.8) 194 (47.7) 0.23
 III 196 (48.2) 213 (52.3)  
Tumor size (cm)
 ≤2 122 (30.0) 126 (31.0) 0.85
 2–5 235 (57.7) 236 (58.0)  
 >5 50 (12.3) 45 (11.0)  
Positive lymph nodes
 1–3 nodes 154 (37.9) 175 (43.0) 0.14
 ≥4 nodes 252 (62.1) 232 (57.0)  
Adjuvant RT
 No 80 (20.6) 103 (25.8) 0.081
 Yes 309 (79.4) 296 (74.2)  
Adjuvant HT
 No 70 (17.3) 84 (20.7) 0.21
 Yes 335 (82.7) 321 (79.3)  
Bone metastases
 No 363 (90.5) 346 (86.7)  
 Yes 38 (9.5) 53 (13.3) 0.090
HER2 statusa
 Negative 290 (75.5) 300 (77.5) 0.51
 Positive 94 (24.5) 87 (22.5)  
Ki67 protein expression
 Low (<20%) 186 (45.7) 179 (44.0)  
 High (≥20%) 221 (54.3) 228 (56.0) 0.62
Subtypes
 Luminal A 125 (33.3) 120 (31.8) 0.021
 Luminal B 128 (34.0) 119 (31.5)  
 Luminal-HER2 58 (15.4) 41 (10.8)  
 HER2-enriched 35 (9.3) 43 (11.4)  
 Triple-negative 30 (8.0) 55 (14.5)  
  1. Comparisons were made using Chi square or Fisher’s exact tests
  2. RT radiation therapy, HT hormonal therapy
  3. Significant p values are shown in italics
  4. aPositive HER2 status: HER2 3+ by IHC or HER2 amplification by FISH